Abbott is transforming care by giving people – and their doctors – timely information to better manage health. We offer chronic care management testing in multiple settings. Our products provide highly accurate test results during the patient consultation, using only a tiny fingerstick or urine sample. The immediate test results provide physicians and patients with the critical information needed to make better decisions for the diagnosis and management of diabetes, cardiovascular disease and their comorbidities.
GP/GPwSI Cardiology, Cardiovascular Lead East Midlands Strategic Network, Nene CCG, Northampton England
Hear Dr Javaid explain the value of Point of Care testing in the management of Diabetes and its comorbidities Cardiovascular risk.
GP Crown Dale Medical Centre, Clinical Lead Lambeth Diabetes Intermediate care team, South London
Hear Dr Chamley explain the many benefits of Point of Care testing that he experiences in his busy clinic in South London England.
The Afinion™ 2 System is a global market leader in highly accurate point-of-care (POC) testing for physician offices and clinics. With the Afinion 2 System, we take the complexity out of the hands of the user and design our tests to be simple and intuitive to use.
See how we manufacture our Afinion products in Olso, which are highly accurate, highly reliable every test every time.
The Cholestech LDX™ System provides highly accurate, CRMLN certified lipid and glucose results in just 5 minutes. It allows healthcare providers to immediately manage patient therapies in the physician office and provides an opportunity for immediate enrollment at on-site employer and community wellness events.
The Cholestech™ LDX provides fast accurate results at the point of care enabling face to face conversations and can help improve office efficiencies.
Measurement of glycated hemoglobin (HbA1c) is central to the management of patients with diabetes. The NycoCard™ READER II is a small battery powered instrument that helps measure HbA1c is 3 minutes to facilitate monitoring long-term glycemic control, adjust therapy and predict the risk for the development of late complications in patient cohorts.
Based on your current location, the content on this page may not be relevant for your country.